Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + R-GEMOX in Transformed DLBCL
NCT03321643Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2018
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events up to 42 days, Maximum tolerated dose up to 28 days and 1 more. Started Sep 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03321643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03321643.